RxDoctor Payments Data

Asif Alavi, MD

Hematology · Detroit, MINPI 1790952562

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,443 of the $17,344 with a category attached, or 83.3%. 5 manufacturers reported payments, led by Vertex at 53.7% of the total. Reporting peaked in 2023 at $9,284 and has fallen 65.3% since, to $3,218 in 2025.

$17,344in general payments, 2019–2025

Across 22 payments — averaging $788.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$9K
  • Sanofi$3K
  • Agios Pharmaceuticals, Inc.$2K
  • Terumo BCT, Inc.$1K
  • Sanofi-aventis U.S. LLC$1K
$810,561in research payments, 2019–2025

Across 243 payments — averaging $3335.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bioverativ Therapeutics Inc.$609K
  • Sanofi US Services Inc.$74K
  • Takeda Pharmaceuticals U.S.A., Inc.$50K
  • Agios Pharmaceuticals, Inc.$44K
  • Pharmacyclics LLC, An Abbvie Company$22K
  • Incyte Corporation$9K
  • plus $2K from 1 others

What the payments were for

  • Consulting fees$14,44383%
  • Travel & lodging$2,46714%
  • Food & beverage$4343%

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex10$9,313
Sanofi2$3,425
Agios Pharmaceuticals, Inc.6$1,694
Terumo BCT, Inc.2$1,495
Sanofi-aventis U.S. LLC2$1,418

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,344 in reported general payments places this provider in the 85th percentile of 50 hematology providers in Michigan.

See all hematology providers in Michigan

Medicare billing

Part B allowed, 2024
$21,609
Medicare patients
99
Services billed
220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxbrytaVoxelotor19$214,832
PromactaEltrombopag Olamine14$203,012
EliquisApixaban23$20,593
Deferasirox23$6,227
Enoxaparin Sodium13$2,638
Morphine Sulfate ErMorphine Sulfate52$1,342
Hydroxyurea24$921
Hydromorphone Hcl40$715
Oxycodone Hcl31$431
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen40$232
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen16$149
Morphine Sulfate12$140
Losartan Potassium11$95
Duloxetine Hcl11$83

Paid to pharmacies, not to this prescriber.

Other hematology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →